- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01548495
Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients (MDS)
March 8, 2012 updated by: yair levy
Investigating Recombinant Human Erythropoietin (rHuEPO) Treatment Efficacy Depending on the Presence of Erythropoietin Autoantibodies in Myelodysplatic Syndrome (MDS) Patients
The purpose of this study is to verify the presents of autoantibodies in serums of MDS serum patients who had an inadequate response or did not respond to Recombinant human erythropoietin (rHuEPO) treatment.
Study Overview
Status
Unknown
Conditions
Detailed Description
MDS are a heterogeneous group of hematologic disorders broadly characterized by cytopenias associated with a dimorphic and usually cellular bone marrow, and by consequent ineffective blood cell production.
85% of patients have a severe anemia which is Associated with lowering quality of life and Often requires blood transfusions.
Historically, only stem cell transplantation offers cure.
however, multiple new drugs have been approved for treatment, such as to Recombinant human erythropoietin (rHuEPO) treatment for dealing with the anemia.
rHuEPO treatment can improve hematocrit level in 25% of patient which leaves the rest with the need of other treatment solution.
Studies have shown presents of anti- rHuEPO in blood serums which followed Treatment of other diseases.
These findings can indicate the possibility of the presence of antibodies in MDS patients as well.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kfar- Saba, Israel, 44531
- Meir Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
MDS patient from meir health care center
Description
Inclusion Criteria:
- Followed up hematological patients
- Pateint recieving rHuEPO treatment (except control group)
- Pateint signed informed consent
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Responded to rHuEPO treatment
response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
|
IR to rHuEPO treatment
No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
|
Responded to high level rHuEPO
Responded to more than 80,000UI of rHuEPO treatment
|
No rHuEPO treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlate the Presence of Erythropoietin autoantibodies titer in MDS patients with an inadequate response (IR) to Human Recombinant Erythropoietin treatment
Time Frame: 1 year
|
Response to Erythropoietine (EPO) was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period. Detection of Erythropoietin autoantibodies was performed by "Home-made ELISA" test. |
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Anticipated)
May 1, 2013
Study Completion (Anticipated)
September 1, 2013
Study Registration Dates
First Submitted
February 28, 2012
First Submitted That Met QC Criteria
March 7, 2012
First Posted (Estimate)
March 8, 2012
Study Record Updates
Last Update Posted (Estimate)
March 9, 2012
Last Update Submitted That Met QC Criteria
March 8, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDS-2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplatic Syndrome
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la Loire; Laboratoire Interuniversitaire de Biologie...TerminatedMyelodysplatic SyndromesFrance
-
Neumedicines Inc.Department of Health and Human ServicesCompletedHematopoietic Syndrome Due to Acute Radiation SyndromeUnited States
-
Ministry of Public Health, Democratic Republic...National Institutes of Health (NIH); Oregon Health and Science University; National... and other collaboratorsCompletedNeurotoxicity Syndrome, Cassava | Neurotoxicity Syndrome, Cyanate | Neurotoxicity Syndrome, Cyanide | Neurotoxicity Syndrome, ThiocyanateCongo, The Democratic Republic of the
-
Mahidol UniversityCompletedSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Subacromial Pain Syndrome | Subacromial Impingement | Impingement Syndrome, ShoulderIndonesia
-
Cliniques universitaires Saint-Luc- Université...TerminatedMultiple Organ Dysfunction Syndrome | SEPTIC SHOCK | SEPSIS SYNDROMEBelgium
-
University of PennsylvaniaRecruitingCRS - Cytokine Release Syndrome | HLHUnited States
-
University of ManitobaTerminatedPatellofemoral Pain Syndrome | Anterior Knee Pain Syndrome | Patellofemoral SyndromeCanada
-
Massachusetts General HospitalUniversity of California, San DiegoNot yet recruitingAuto-Brewery Syndrome | Gut Fermentation SyndromeUnited States
-
University of NottinghamMedical Research Council; National Institute for Health Research, United KingdomRecruitingFrail Elderly Syndrome | Frailty | Frailty SyndromeUnited Kingdom
-
Riphah International UniversityCompleted